Natco Pharma unveils first generic version of Pomalyst capsules in Australia
Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma.
Hyderabad: Drugmaker, NATCO Pharma Limited, today announced the launch of first generic version of Pomalyst (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCO's commercial partner Juno Pharmaceuticals Pty Ltd. Pomalidomide is prescribed for the treatment of Multiple Myeloma and Kaposi Sarcoma. Multiple myeloma is...
Hyderabad: Drugmaker, NATCO Pharma Limited, today announced the launch of first generic version of Pomalyst (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market.
The product was launched by NATCO's commercial partner Juno Pharmaceuticals Pty Ltd.
Pomalidomide is prescribed for the treatment of Multiple Myeloma and Kaposi Sarcoma.
Multiple myeloma is an uncommon type of blood cancer in which abnormal plasma cells build up in the bone marrow and form tumors in many bones of the body. This disease keeps the bone marrow from making enough healthy blood cells, which can result in low blood counts. Myeloma can also damage the bones and the kidneys and weaken the immune system.
Read also: NATCO Announces Launch of the First Generic Version of Revlimid, in the U.S. market
Pomalyst registered sales of USD 35.6 million in the Australian market for the year ending 31st March 2022 as per industry sales data.
Pomalyst is a registered trademark of Celgene/BMS. All brand names and trademarks are the property of their respective owners.
Read also: Natco Pharma launches Chlorantraniliprole (CTPR) pesticide formulated combination products in India
Natco Pharma Limited is a vertically integrated and R&D-focused pharmaceutical company engaged in developing, manufacturing, and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.
Natco sells its FDF products in the United States, India, Europe, and the rest of the world ("RoW"). In the API segment, the company has the capabilities to develop and manufacture products with multi-step synthesis, semi-synthetic fusion technologies, high-potency APIs, and peptides.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Read also: Natco Pharma partner Viatris to launch first generic version of Nexavar tablets in US
